Tear Interleukin Biomarkers After Glaucoma Treatment

Sponsor
Kazakh Eye Research Institute
Study ID
NCT07592988
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MicroPulse Transscleral Cyclophotocoagulation — PROCEDURE
    MicroPulse transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. The procedure will be applied transsclerally over the ciliary body using micropulse laser energy. Tear fluid samples will be collected before treatment, 5-7 days after the procedure, and 1 month postoperatively for assessment of interleukin levels. Intraocular pressure will be measured at the same time points.
  • Conventional Transscleral Cyclophotocoagulation — PROCEDURE
    Conventional continuous-wave transscleral cyclophotocoagulation will be performed as a laser procedure for the treatment of glaucoma. The procedure will be applied transsclerally over the ciliary body using continuous-wave laser energy. Tear fluid samples will be collected before treatment, 5-7 days after the procedure, and 1 month postoperatively for assessment of interleukin levels. Intraocular pressure will be measured at the same time points.
  • Antiglaucoma Surgery — PROCEDURE
    Incisional antiglaucoma surgery will be performed for the treatment of glaucoma according to the clinical indication and standard surgical protocol. Tear fluid samples will be collected before surgery, 5-7 days after surgery, and 1 month postoperatively for assessment of interleukin levels. Intraocular pressure will be measured at the same time points.

Study Details

This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.

Key Dates

First listed
May 18, 2026
Start date
May 18, 2026
Status verified
May 2026
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MicroPulse Transscleral Cyclophotocoagulation Group
    Participants in this group will undergo MicroPulse transscleral cyclophotocoagulation for the treatment of glaucoma. Tear samples and intraocular pressure measurements will be collected before treatment, 5-7 days after the procedure, and 1 month postoperatively to evaluate inflammatory biomarker changes and treatment response.
  • Active Comparator: Conventional Transscleral Cyclophotocoagulation Group
    Participants in this group will undergo conventional continuous-wave transscleral cyclophotocoagulation for the treatment of glaucoma. Tear samples and intraocular pressure measurements will be collected before treatment, 5-7 days after the procedure, and 1 month postoperatively to evaluate inflammatory biomarker changes and treatment response.
  • Active Comparator: Antiglaucoma Surgery Group
    Participants in this group will undergo incisional antiglaucoma surgery for the treatment of glaucoma. Tear samples and intraocular pressure measurements will be collected before surgery, 5-7 days after surgery, and 1 month postoperatively to evaluate inflammatory biomarker changes and treatment response.

Primary Outcome Measure

Association Between Changes in Tear Fluid Interleukin Levels and Intraocular Pressure Reduction [ Time Frame: Baseline, 5-7 days after treatment, and 1 month after treatment ]

Central Contacts

Find similar trials

Nationwide
Glaucoma trialsOphthalmology trials

Related Studies